Trials / Conditions / Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

23 registered clinical trials studyying Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 — 11 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cann NCT07441681	NRG Oncology	Phase 3
Recruiting	Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Ca NCT07195734	National Cancer Institute (NCI)	Phase 2
Not Yet Recruiting	Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squ NCT07156227	National Cancer Institute (NCI)	Phase 1
Recruiting	Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy f NCT06532279	NRG Oncology	Phase 2
Recruiting	Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluati NCT06914999	Emory University	EARLY_Phase 1
Recruiting	De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA NCT05541016	Mayo Clinic	Phase 2
Recruiting	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196	National Cancer Institute (NCI)	Phase 2
Recruiting	Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer NCT05172245	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr NCT04576091	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Pap NCT05232851	Mayo Clinic	Phase 1 / Phase 2
Suspended	Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advan NCT05050162	NRG Oncology	Phase 2 / Phase 3
Active Not Recruiting	Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cance NCT04533750	National Cancer Institute (NCI)	Phase 1
Unknown	Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With T NCT04920344	Rutgers, The State University of New Jersey	Phase 2
Recruiting	Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Stud NCT04900623	Jonathan Schoenfeld, MD, MPH	Phase 2
Withdrawn	Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer NCT04140513	Ohio State University Comprehensive Cancer Center	N/A
Completed	Study of Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration in HPV+ Head and Neck Cancer of Unkn NCT04489212	Mayo Clinic	N/A
Terminated	Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant NCT04106362	Jonsson Comprehensive Cancer Center	Phase 2
Terminated	Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer NCT04162873	University of Utah	Phase 2
Recruiting	Oropharynx (OPX) Biomarker Trial NCT06356272	Mayo Clinic	—
Active Not Recruiting	Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer NCT03811015	National Cancer Institute (NCI)	Phase 3
Terminated	Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Par NCT03618134	Jonsson Comprehensive Cancer Center	Phase 1 / Phase 2
Completed	Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck NCT03258554	National Cancer Institute (NCI)	Phase 2 / Phase 3
Recruiting	Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With NCT03010150	M.D. Anderson Cancer Center	—